Immunocore
Logotype for Immunocore Holdings plc

Immunocore (IMCR) investor relations material

Immunocore UBS Global Biopharma Conference 2026 summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Immunocore Holdings plc
UBS Global Biopharma Conference 2026 summary17 Nov, 2026

KIMMTRAK commercial outlook

  • KIMMTRAK is standard of care across major markets, with 70%+ penetration; growth is moderating as the product matures.

  • U.S. growth focus: deeper community-setting penetration and patient access; OUS growth mainly from new launches, patient access, and longer treatment duration in newer markets.

  • Duration of therapy is ~14 months in major markets launched for 4–5 years, versus ~10–11 months in clinical studies; U.S. duration has mostly stabilized.

Uveal melanoma combination and competition

  • Phase 1/2 study enrolled patients with unresectable or metastatic HLA-A*02:01-positive mUM; brenetafusp monotherapy enrolled 22 patients and combination with tebentafusp enrolled 26; data cutoff was June 2026.

  • In the 1L combination cohort (n=17), ORR was 29%, DCR 71%, median DOR 24.1 months and PFS 8.1 months; median OS was not reached, with 70% 2-year OS at 29 months’ median follow-up.

  • Monotherapy evaluable patients (n=16; 2L+) had 19% ORR, 63% DCR, median DOR 14.5 months, PFS 4.2 months and OS 20.3 months; 23% had prior tebentafusp.

  • TRAEs occurred in 100% of both cohorts; grade 3/4 TRAEs occurred in 45% with monotherapy and 38% with combination. No TRAE led to discontinuation or death; no new combination safety signals were reported.

  • Dual gp100/PRAME targeting aims to increase tumor engagement and T-cell killing; combination data compared favorably with historical tebentafusp monotherapy datasets in a cross-trial comparison. Randomized evaluation was in planning.

TEBE-AM in advanced cutaneous melanoma

  • Phase III TEBE-AM tests KIMMTRAK plus pembrolizumab in refractory advanced cutaneous melanoma; rationale includes GP100 expression of 85%+ in uveal and cutaneous tumors and activity of both agents.

  • Enrollment completed in the prior quarter; OS-driven results are expected in Q2 2027. Management advised against reading into the timing shift because the study is blinded.

  • Eligible patients must have failed ipilimumab/nivolumab and, if BRAF-mutant eligible, BRAF therapy; control allows locally available treatment, including retreatment, chemotherapy, palliative care or trials.

  • Expected control-arm OS is ~10–11 months based on real-world treatment mix; management said a statistically significant OS benefit would support commercial prospects.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Immunocore earnings date

Logotype for Immunocore Holdings plc
Q4 202624 Feb, 2027
Immunocore
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Immunocore earnings date

Logotype for Immunocore Holdings plc
Q4 202624 Feb, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Immunocore Holdings plc is a commercial-stage biotechnology company focused on the development of innovative immunotherapies for cancer, infectious diseases, and autoimmune diseases. Utilizing its proprietary T cell receptor (TCR) technology, the company aims to create transformative medicines to address unmet medical needs. Among its notable products is KIMMTRAK, designed for the treatment of patients with unresectable or metastatic uveal melanoma. Immunocore is headquartered in Abingdon, the United Kingdom, and is listed on the NASDAQ stock exchange under the ticker symbol IMCR.